HB0017 vs Roconkibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-17A · full Psoriasis pipeline
HB0017
Developed by Huabo Biopharm Co.
NCT06477237 · Phase 3 · completed
This is a randomized, quadruple-blind, placebo-controlled Phase 3 trial using validated psoriasis response measures as its primary endpoints, but no results are yet posted to the registry, so the outcome is unknown.
Next expected readout: December 2026 · NCT07920861 (registry estimate)
Reported efficacy
PASI 90 response (Week 12); sPGA 0/1 response (Week 12): Co-primaries PASI 90 and sPGA 0/1 at week 12: HB0017 300 mg (n=41) vs placebo (n=40), PASI 90 69.4% vs 1.0% and sPGA 0/1 78.2% vs 1.1%, both P<0.001. The registry lists three HB0017 dosing regimens and 160 participants; the abstract reports one regimen in 81 patients and gives no result for the other two regimens. (unclear)
Result source: NCT05531682
Roconkibart
Developed by Shanghai Junshi Bioscience and partners
NCT05975268 · Phase 3 · completed
The trial randomized participants to JS005 150mg, 300mg, or placebo with full blinding of participants, care providers, investigators, and outcomes assessors, in a reasonably large phase 3 population of 747 patients. The primary endpoints -- PASI 90 and sPGA 0/1, both standard hard clinical measures of psoriasis severity -- were reported as met with statistically significant improvement over placebo, satisfying the design and result standards for strong evidence.
Result from the sponsor's press release or a wire copy of it; no peer-reviewed publication or posted registry results were found.
Reported efficacy
Change in PASI 90 (From week 0 to week 12); Change in sPGA (From week 0 to week 12): Both co-primary endpoints and key secondary endpoints showed statistically significant and clinically meaningful improvements (met)
Result source: NCT05975268
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HB0017 | Roconkibart |
|---|---|---|
| PASI 75 | —Not posted · NCT06477237 | —Not posted · NCT05975268 |
| PASI 90 | —Not posted · NCT06477237 | —Not posted · NCT05975268 |
| PASI 100 | —Not posted · NCT06477237 | —Not posted · NCT05975268 |
| sPGA 0/1 | —Not posted · NCT06477237 | —Not posted · NCT05975268 |
| DLQI, change | —Not posted · NCT06477237 | —Not posted · NCT05975268 |
PASI 75
- HB0017
- —Not posted · NCT06477237
- Roconkibart
- —Not posted · NCT05975268
PASI 90
- HB0017
- —Not posted · NCT06477237
- Roconkibart
- —Not posted · NCT05975268
PASI 100
- HB0017
- —Not posted · NCT06477237
- Roconkibart
- —Not posted · NCT05975268
sPGA 0/1
- HB0017
- —Not posted · NCT06477237
- Roconkibart
- —Not posted · NCT05975268
DLQI, change
- HB0017
- —Not posted · NCT06477237
- Roconkibart
- —Not posted · NCT05975268
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HB0017's landscape · Roconkibart's landscape